Nanning (1)

Advanced Unresectable Hepatocellular Carcinoma (1)

Lenvatinib (1)

TACE (1)

Tislelizumab (1)

Active, not recruiting (1)

early phase 1 (1)

Cancer Hospital of Guangxi Medical University (1)

tislelizumab and lenvatinib (1)

combination product (1)

Other (1)

Interventional (1)

advanced unresectable hepatocellular carcinoma

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Active, not recruiting

Nanning, Guangxi, China

The Affiliated Cancer Hospital of Guangxi Medical University

Jan 25, 2023